99% of evaluable treated patients showed immune responses to a cancer mutation. The trial missed its main goal.
Elicio Therapeutics (ELTX) reported Phase 2 trial results for camupepimut (ELI-002 7P) in pancreatic cancer, missing the primary DFS endpoint but showing favorable trends in subgroups. Key findings: 99% of patients showed immune responses, and DFS improvements were observed in ctDNA-negative (HR 0.51) and ctDNA-positive (HR 0.57) patients. The company plans to discuss Phase 3 study design with the FDA.
How this was made
The 30-second read
Why it matters
The data provides the first efficacy readout for camupepimut, influencing ELTX's valuation and future financing prospects.
Market read
Primary disclosure of Phase 2 trial data for a US-listed biotech; high relevance for investors tracking oncology immunotherapies.
What to watch
Baseline ctDNA imbalances and subgroup benefits suggest potential for refined patient selection in Phase 3.
Background
Elicio Therapeutics is a clinical-stage biotech focusing on KRAS-driven cancer vaccines. The AMPLIFY-7P Phase 2 trial results were presented at ESMO 2026 and published in Nature Medicine.
Ticker impact
Elicio Therapeutics (ELTX) disclosed Phase 2 trial results for camupepimut, showing immune responses in 99% of patients and mixed efficacy signals.
potential near-term pressure from missed primary endpoint, offset by upside from strong immune response data
First disclosure of trial data; investors will reassess valuation based on efficacy signals and future Phase 3 prospects.
Market effects
Phase 2 KRAS vaccine data may influence broader biotech and immunotherapy sector sentiment.
U.S. biotech investors may adjust exposure to early-stage cancer vaccine developers.
Limited to biotech investors; no broad market effect.
Counterpoint
Despite the missed primary endpoint, the strong immune response could signal a differentiated mechanism worth a longer-term hold.
Key entities
- CompanyElicio Therapeutics, Inc.
Developer of camupepimut (ELI-002 7P) vaccine.
- ExecutiveRobert Connelly
President and CEO of Elicio, quoted on trial results.
